A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
Abstract
Bevacizumab [Avastin; anti–vascular endothelial growth factor (VEGF) antibody] is an antiangiogenic IgG approved for treating patients with certain types of colon, breast, and lung cancer. In these indications, bevacizumab is administered every 2 to 3 weeks, prompting us to study ways to reduce the frequency of administration. Increasing affinity to neonatal Fc receptor (FcRn) may extend the pharmacokinetic half-life of an antibody, but the...
Paper Details
Title
A Therapeutic Anti–VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life
Published Date
Apr 14, 2010
Journal
Volume
70
Issue
8
Pages
3269 - 3277
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History